Research Synthesis: Fasting Intervention Time Restricted Eating Tre Effects

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Replace the 20× repeated 'Additional corpus sources included animal/preclinical evidence' placeholder in Evidence Snapshot and Results with the actual source identifiers and substantive claims; remove the broken author token 'semnani-' and replace with the correctly cited 'Semnani-Azad 2025'.
2. Either add Ioannidis 2005, WHO 2000, and ADA 2024 to the source bundle and reference list with DOIs/PMIDs, or remove the in-text references and replace with sources actually in the 19-source corpus. The methodological Ioannidis anchor in particular must be supported by an in-bundle source or removed.
3. Resolve the Sampieri 2024 P-value inconsistency: pick one value (0.001 vs 0.003) and ensure it matches between Findings Map, Evidence Snapshot, and any prose mention.
4. Reconcile Cozma 2025's evidence_type classification (primary vs review) between the Methods extraction table and the in-text description, and update the directness/tier assignment accordingly.
5. Rewrite the Research Question section to state a specific, answerable question rather than reproducing the Abstract verbatim; the question should be one the cited corpus can directly address (e.g., whether direct RCT evidence supports a cardiometabolic benefit of TRE in adults, and under what boundary conditions).
6. Remove or substantially condense the repeated 'bounded / not a guideline / structured map' boilerplate across Abstract, Background, Conclusion, Discussion, and Cross-Domain Synthesis; replace with section-specific synthesis content.
7. Fix paragraph breaks and formatting in the Results section so individual outcome-class sub-sections are readable and not merged into dense blocks.
8. Tighten Cross-Domain Synthesis to focus on the three or four real tensions actually supported by the bundle (direct RCT vs indirect cohort; null vs negative; surrogate vs hard endpoint; shift-worker boundary) rather than introducing methodological anchors not in the corpus.
9. Reclassify Karras 2021/2023/2024 descriptions consistently across Cross-Domain Synthesis and Findings Map — either as observational cohorts (and update bundle directness/tier) or as indirect primary research, but the same label in both places.

Major issues

• Findings Map / Evidence Snapshot contains pathological repetition: 'Additional corpus sources included animal/preclinical evidence;' is repeated ~20 times as a fill-in token rather than a substantive claim, indicating malformed prose rendering and undermining the synthesis quality and traceability.
• Cross-Domain Synthesis references 'semnani-' (broken author token) and 'ADA 2024 (7% standard, 6.5% tighter goal)' without citing a specific source from the bundle; HbA1c thresholds are introduced without source attribution despite the manuscript's claim of source-traced numerics.
• Cross-Domain Synthesis cites Ioannidis 2005 as a methodological anchor but Ioannidis 2005 is NOT present in the 19-source bundle; this is an uncited reference and an unsupported escalation source.
• Cross-Domain Synthesis cites 'WHO 2000' obesity threshold and 'ADA 2024' without bundle entries, breaking the source-traceability standard the manuscript itself promises.
• Evidence Snapshot entry for Sampieri 2024 lists representative statistic P = 0.001, but the Findings Map row for Sampieri 2024 lists P = 0.003 — internal numeric inconsistency.
• Cross-Domain Synthesis paragraph assigns Karras 2021 and Karras 2024 to the observational-cohort block but the bundle and Findings Map classify them as 'indirect' primary research, not observational cohorts; the clean RCT-vs-observational dichotomy stated is not consistently supported by the bundle classifications.
• Abstract and Conclusion use the same generic 'bounded evidence case / ceiling / map' boilerplate; the synthesis does not produce a research question specific enough to be directly answered by the cited corpus, and the research question section repeats the abstract text verbatim rather than articulating the question.

Minor issues

• Load-Bearing Included Studies list repeats 'Additional corpus sources included animal/preclinical evidence' 20 times as a stub instead of listing actual sources, breaking the traceability promise of the snapshot.
• Title field reads 'full paper' suffix as artifact of submission; should be cleaned for publication surface.
• Cross-Domain Synthesis 'Boundary-condition synthesis' subsection restates generic safe-conclusion language ('not a treatment guideline', 'structured map') that adds little beyond what the Conclusion already states.
• Some Findings Map 'finding' cells report raw claim counts (e.g., 202 extracted claims) rather than study-level findings, reducing table readability.
• Several paragraph breaks in the Results section are missing or merged, producing dense unreadable blocks (e.g., 'Quantitative cardiometabolic findings cluster around three patterns. the evidence synthesis cross-references every study × p-value tuple...').
• The Discussion repeats the cross-study disagreement framing that is already in the Cross-Domain Synthesis without advancing interpretation.
• Reference list contains 'Semnani-Azad 2025' but manuscript prose writes 'semnani-' and 'Semnani-' inconsistently, suggesting broken reference rendering.
• Cozma 2025 is described as a narrative review in the bundle, but the Methods classify it as primary research (evidence_type=primary); inconsistent classification affects directness interpretation.

Reviewer note

This is a 19-source scoping synthesis on time-restricted eating (TRE) with cardiometabolic as the dominant outcome class. The manuscript follows a recognizable house template (Methods with PRISMA-ScR framing, Findings Map, Evidence Snapshot, Cross-Domain Synthesis, Limitations, Conclusion) and the source bundle is mostly real, recent, and traceable. The abstract and conclusion appropriately hedge given that 14/19 sources are indirect/review-level, and the Limitations section is substantive — naming the absence of long-term hard-endpoint trials, narrow population bands, and the surrogate-endpoint problem. The cross-domain section identifies real tensions (direct RCT vs indirect cohort; null vs negative; surrogate vs hard outcome; shift-worker boundary), which is the right move for this corpus. However, several integrity defects prevent an accept call. First, the Findings Map and Evidence Snapshot contain pathological prose: 'Additional corpus sources included animal/preclinical evidence;' is repeated ~20 times as a fill-in token, which is a malformed-rendering artifact and breaks the traceability promise. Second, the Cross-Domain Synthesis introduces three references that are not in the source bundle (Ioannidis 2005, WHO 2000, ADA 2024), and cites a broken author token ('semnani-') for Semnani-Azad 2025 — the very methodology-vs-source-traceability standard the manuscript claims to meet is violated at multiple points. Third, internal numeric inconsistency: Sampieri 2024's representative p-value is 0.001 in the Evidence Snapshot but 0.003 in the Findings Map. Fourth, the Research Question section reproduces the Abstract verbatim rather than stating an answerable question, weakening the research_question_quality score. On balance the manuscript is salvageable with bounded edits — the bundle is mostly solid, the Limitations are real, the bounded conclusion is honest — but the rendering artifacts, uncited references, and numeric inconsistency must be resolved before the paper is publishable. Recommendation: revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: sparring_failed_primary_used

Prompt: reviewer-v11-research-synthesis